FDA Panel Rejects Combo Drug for PTSD
An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti,…
First New PTSD Drug in Two Decades On the Horizon?
The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…
FDA Approves First Treatment for MAS in Still Disease
The FDA has approved the interferon gamma-blocking antibody emapalumab-lzsg (Gamifant) for the treatment of macrophage activation syndrome (MAS)…
Injectable HIV Prevention Drug Gets FDA Nod
Individuals at risk for sexually acquired HIV have a new injectable option for preexposure prophylaxis (PrEP) with the…
FDA Approves Triple Rx for Hypertension
The FDA has approved Widaplik, a triple-drug combination, for the treatment of hypertension in adults. Widaplik combines three…
Clinicians Push FDA on NarxCare
This article is the second in a series on prescription drug monitoring programs and analysis tools designed to…
FDA Issues Warning on ‘Gas Station Heroin’ Tianeptine
The US Food and Drug Administration (FDA) has issued a health warning regarding products containing tianeptine, which is…
FDA Okays Upadacitinib for Giant Cell Arteritis
The US Food and Drug Administration (FDA) has approved a new indication for upadacitinib as a treatment for…
FDA Issues Alert on Compounded Topical Finasteride Risks
The US Food and Drug Administration (FDA) said Tuesday it has become aware of reports of adverse events…
FDA Authorizes First Digital Therapeutic for Migraine
The US Food and Drug Administration (FDA) has granted marketing authorization to CT-132 (Click Therapeutics), an adjunctive, first-in-class…